FunPep Co., Ltd.
TTSE:488142.00
JPY
-1.00
(-2.33%)
ISIN
JP3802640007
Return %
Stock
S&P 500
1Y
-58.00
14.20
3Y
-72.90
81.12
5Y
-87.65
68.34
Capital Structure
JPY
•
in mil. unless spec.Working Capital
JPY
•
in mil. unless spec.Growth Rates
JPY
•
in mil. unless spec.Quarterly Revenue
JPY
•
in mil. unless spec.Quarterly Earnings Per Share
JPY
•
in mil. unless spec.Quarterly Dividends Per Share
JPY
•
in mil. unless spec.Company Description
- CEO
- Toshimi Miyoshi
- Full Time Employees
- 15
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 7-15, Saito Asagi 7-chome Osaka OS Japan 151-0051
- IPO Date
- Dec 25, 2020
- Website
- funpep.co.jp
- Similar Companies
- Business
- FunPep Company Limited engages in the research and development of pharmaceuticals, functional cosmetics, and medical devices based on functional peptides. Its core products include functional peptides such as SR-0379 for skin ulcer treatment; antibody-inducing peptides including FPP003, which is in Phase II clinical trials for the treatment of psoriasis in Australia and ankylosing spondylitis in Japan; FPP004X, an antibody-inducing peptide vaccine for pollinosis currently in preclinical trials; FPP006, a corona peptide vaccine; and FPP005, an antibody including peptide for psoriasis. The company also focuses on next-generation formulation technology for antibody-inducing peptides aiming to provide alternatives to expensive antibody drugs and reduce healthcare costs. FunPep operates primarily in Japan but conducts clinical studies internationally, emphasizing unmet medical needs in skin ulcer and autoimmune disease therapeutics. Incorporated in 2013 with headquarters in Tokyo, Japan, FunPep collaborates strategically to advance its pipeline, notably signing a strategic agreement with BIOASTER in March 2025 to optimize an in vitro assay to induce a human B cell immune response for its leading candidates. The company also executed an option agreement with Shionogi regarding an allergy vaccine and has ongoing collaborations to develop antibody-inducing peptide therapies. In 2025, FunPep received ¥3.6 million in funding from SBI Securities and concluded an option agreement with Sumitomo Pharma over the FPP003 peptide, which Sumitomo declined to exercise. These strategic partnerships and funding support FunPep's clinical trials and platform development in functional peptide therapeutics for various chronic and immune-related diseases.